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AbstrAct
Aim Contemporary data comparing early versus newer 
generation transcatheter heart valve (THV) devices in 
routine clinical practice are lacking. We sought to compare 
the safety and efficacy of early versus newer generation 
THVs in unselected patients undergoing transcatheter 
aortic valve implantation (TAVI).
Methods and results We performed a propensity score 
matched analysis of patients undergoing transfemoral 
TAVI at a single centre with early versus newer generation 
devices between 2007 and 2016. Patients were matched 
for balloon-expandable versus self-expandable valves and 
Society of Thoracic Surgeons score. The primary end point 
was the Valve Academic Research Consortium (VARC)-2 
early safety composite end point at 30 days. Among the 
391 matched pairs, no differences between early (21.2%) 
and newer generation (20.8%) THVs regarding the early 
safety composite end point (HR 0.98, 95% CI 0.72 to 1.33, 
P=0.88) were observed. The rates of valve embolisation 
(0.8% vs 4.2%, P=0.005), bleeding events (24.8% vs 
32.0%, P=0.028) and moderate-to-severe paravalvular 
regurgitation (PVR) (3.1% vs 12.1%, P<0.001) were lower 
among patients receiving newer generation devices. 
Conversely, patients treated with early generation THVs 
less frequently experienced annulus rupture (0% vs 2.0%, 
P=0.008).
Conclusion Newer compared with early generation 
THV devices were associated with a lower rate of valve 
embolisation, PVR and bleeding events.
IntroduCtIon
Transcatheter aortic valve implantation 
(TAVI) has rapidly evolved as a treatment 
strategy for inoperable patients with severe 
aortic stenosis (AS) and as a viable therapeutic 
alternative to surgical aortic valve replace-
ment (SAVR) among high-risk and interme-
diate-risk patients. TAVI using the first-gen-
eration balloon-expandable (Edwards 
SAPIEN and SAPIEN XT, Edwards Lifes-
ciences, Irvine, California, USA) transcath-
eter heart valve (THV) device was shown to 
be superior to the guideline-directed medical 
therapy and non-inferior to SAVR at 11 and 
5 years follow-up.2 In addition, TAVI using 
the self-expandable CoreValve (Medtronic, 
Minneapolis, Minnesota, USA) was observed 
to be superior to SAVR at 3-year follow-up.3 
However, first-generation THV devices are 
associated with issues including paravalvular 
aortic regurgitation (PVR), vascular compli-
cations, strokes and conduction disturbances. 
In particular, moderate-to-severe PVR is 
significantly higher following TAVI with early 
generation THV devices as compared with 
Key questions
What is already known about this subject?
 ► First-generation transcatheter heart valve (THV) 
devices are associated with issues including 
paravalvular aortic regurgitation, vascular 
complications, strokes and conduction 
disturbances, which are associated with worse 
prognosis.
 ► Data on newer generation THVs are mainly derived 
from registries focusing on one particular valve 
type and unselected data on all-comer patients 
receiving any newer generation THV are lacking.
What does this study add?
 ► This study provides evidence that the newer 
generation THVs are as safe as the early generation 
devices regarding the comparable Valve Academic 
Research Consortium-2 early safety composite 
end points.
 ► The specific designs of the newer generation THVs 
are of benefit to reduce THV migration, bleeding 
complications and paravalvular regurgitation.
How might this impact on clinical practice?
 ► A tailored use of THV devices based on patient 
anatomical and prosthesis characteristics may 
exploit the full potential of these new devices.
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SAVR and is associated with impaired prognosis during 
medium-term to long-term follow-up.4 5 Subsequent itera-
tions of early generation self-expandable and balloon-ex-
pandable devices feature smaller delivery sheaths, more 
controllable deployment mechanisms and circumferen-
tial cuffs and skirts to address the aforementioned limita-
tions of first-generation THV devices.6 Hitherto, data on 
newer generation THVs are mainly derived from regis-
tries focusing on one particular valve type and unselected 
data on all-comer patients receiving any newer genera-
tion THV are lacking.7–9
Therefore, the objective of our study was to compare 
30 day safety and efficacy of early and newer genera-




All patients undergoing TAVI at Bern University Hospital 
are consecutively enrolled in a prospective registry. For 
the purpose of the present analysis, we investigated all 
patients treated by transfemoral access and excluded 
patients with alternative access. The selection of patients 
with severe AS eligible for TAVI, device allocation and 
periprocedural management was left to the discretion 
of the operators. The antiplatelet and antithrombotic 
regimen has not been modified throughout the entire 
period of inclusion and consisted of dual antiplatelet 
therapy for 6 months in patients with no indication for 
oral anticoagulation. One antiplatelet agent was added 
in patients with indication of oral anticoagulation and 
recent stent implantation, and oral anticoagulation 
alone was prescribed in all other patients. All data were 
recorded in a web-based database held at the Clin-
ical Trial Unit at the University of Bern, Switzerland. 
The Bern TAVI registry has been approved by the local 
cantonal Ethics Committee. All patients provided written 
informed consent to participate to this registry.
devices
All TAVI devices used for transfemoral access were dichoto-
mised into early and newer generation devices. Medtronic 
CoreValve, Edwards SAPIEN THV and Edwards SAPIEN 
XT were considered early generation devices, whereas 
Edwards SAPIEN 3 (Edwards Lifesciences), LOTUS valve 
system (Boston Scientific, Natwick, Massachusetts, USA) 
and Medtronic Evolut R (Medtronic) were considered 
newer generation devices. All these newer generation 
THV devices are available since 2014 for commercial use 
and implantation in Switzerland.
definitions and follow-up
After discharge following the index hospitalisation, 
patients were contacted the first time for a 30-day clin-
ical follow-up. Standardised interviews, documentation 
from referring physicians and hospital discharge summa-
ries were used for the collection of clinical end points. 
All safety and efficacy end points were defined according 
to the updated version of the Valve Academic Research 
Consortium (VARC-2) definition.10 All adverse events 
were adjudicated by an independent Clinical Events 
Committee. The primary prespecified end point of our 
analysis was the VARC-2 early safety outcome, a composite 
of all-cause death, stroke, life-threatening bleeding, acute 
kidney injury stage 2 or 3, coronary obstruction requiring 
intervention, major vascular complications and valve-re-
lated dysfunction requiring repeat procedure.
statistical analysis
Patients were matched on Society of Thoracic Surgeons 
(STS) predicted risk of mortality score within the 
non-self-expandable devices (generating Edwards 
SAPIEN THV/XT vs SAPIEN 3 matched pairs, n=190 
pairs) and separately on STS score within the self-expand-
able devices (generating Medtronic CoreValve vs Evolut R 
or Boston Scientific LOTUS matched pairs, n=201 pairs—
including n=105 Evolut R and n=96 LOTUS). Contin-
uous data are reported as mean±SD and compared using 
the Student’s t-test. Categorical variables are reported as 
counts and percentages and were compared using the 
Χ2 or Fisher’s exact test, as appropriate. Event rates at 30 
days were compared for patients who underwent newer 
versus early generation THV devices implantation using 
Cox’s regression, censoring patients at death or lost to 
follow-up. Reported are crude HRs with 95% CIs, with 
P values from Wald Χ2 tests comparing newer versus early 
generation THV devices, or continuity correct risk ratio 
with P values from Fisher’s exact tests in case of zero 
events, throughout. Landmark analyses were performed 
using a landmark set at 3 days since the TAVI procedure. 
HRs per period (0–3 days, or 4–30 days) were again calcu-
lated using Cox’s regressions for each period separately, 
and whether these HRs differed per period were tested 
using an interaction test (THV generation x period) with 
robust SEs. Stratified analysis of the following subgroups 
were performed: age (≥80 years vs <80 years), gender 
(female vs male), diabetes (diabetic vs non-diabetic), 
atrial fibrillation (yes vs no), left ventricular ejection frac-
tion (≤30% vs >30%, n=89 patients with missing data), 
renal failure with an estimated glomerular filtration 
rate <30 mL/min (yes vs no, n=3 patients with missing 
data), peripheral artery disease (yes vs no) and addition-
ally the P value for interaction between subgroups and 
device generation is reported.
For all analyses, a two-sided α<0.05 was considered 
to be statistically significant. All statistical analyses were 
performed using the Stata software, V.14.2 (StataCorp, 
College Station, Texas, USA).
results
Patient population
Among 1232 patients undergoing TAVI at Bern Univer-
sity Hospital between 14 August 2007 and 30 June 2016, 
we derived 391 propensity score matched pairs (figure 1). 
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Baseline characteristics were well balanced between the 
two groups (table 1).
As compared with patients treated with the newer 
generation THV devices, those treated with the early 
generation THV had a higher prevalence of renal failure 
(38.3% vs 24,7%, P<0.001), and a lower prevalence of 
carotid artery disease (5.5% vs 10.6%, P=0.017).
Procedural characteristics
Procedural characteristics are summarised in table 2.
Procedure time was significantly shorter (63.2±27.8 vs 
68.8±34.2 min, P=0.014) and contrast volume significantly 
lower (161±57 vs 234±99 mL; P<0.001) in patients treated 
with newer as compared with earlier generation THV 
devices, respectively. Patients treated with newer gener-
ation devices less frequently underwent predilatation 
(58.8% vs 88.5%, P<0.001). The rate of valve migration 
or embolisation was significantly lower among patients 
receiving newer as compared with an early generation 
devices (0.8% vs 4.0%, P<0.001). Conversely, patients 
treated with early generation devices less frequently expe-
rienced annulus rupture and/or aortic dissection (0% vs 
2.0%, P=0.008). Patients treated with newer generation 
THV devices had a lower rate of moderate or severe 
PVR (3.1%) as compared with patients treated with early 
generation devices (12.1%) (P<0.001).
thirty-day clinical outcomes
Clinical follow-up at 30 days was complete in all patients. 
The VARC-2 early safety composite end point was 
observed in 20.8% of patients treated with newer gener-
ation THV devices and in 21.2% of patients treated with 
early generation THV devices (HR 0.98, 95% CI 0.72 to 
1.33, P=0.876) (figure 2). A landmark analysis set at 3 
days showed no differences in timing of events between 
the two groups in the early or late phase after TAVI, 
respectively (figure 3). The individual components of the 
primary composite end point are reported in table 3.
There were no significant differences between 
patients treated with early versus newer generation 
THV devices with regard to all-cause mortality (4.9% 
vs 3.9%, HR 0.80, 95% CI 0.41 to 1.58, P=0.519) and 
stroke (4.1% vs 3.9%, HR 0.94, 95% CI 0.47 to 1.91, 
P=0.868). Bleeding events were more common among 
patients treated with early as compared with newer 
generation devices (32.0% vs 24.8%, HR 0.74, 95% CI 
0.57 to 0.97, P=0.028), whereas the rates of vascular 
access site complications were comparable (major or 
minor, 24.8% vs 23.9%, HR 0.96, 95% CI 0.72 to 1.27, 
P=0.757). In a stratified analysis for the VARC-2 early 
safety outcome, there were no significant interactions 
across major subgroups (figure 4).
Figure 1 Flow diagram of patients included into the propensity score matched analysis. *Patient censored at last scheduled 
or unscheduled contact. BSC, Boston Scientific; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve.
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dIsCussIon
We present a propensity score matched comparison of 
clinical outcomes among unselected patients treated with 
early versus newer generation THV devices in routine 
clinical practice. The main findings of the present anal-
ysis can be summarised as follows: (1) there was no signif-
icant difference in the risk of the 30-day VARC-2 safety 
composite end point between early and newer generation 
THV devices; (2) newer generation devices decreased 
the risk of valve migration or embolisation; (3) moderate 
or severe PVR occurred less frequently with newer as 
compared with earlier generation THV devices; (4) there 
was a decreased risk of bleeding among patients treated 
with newer generation devices.
There were no significant differences in the composite 
early safety outcome between patients treated with 
early as compared with newer generation THV devices. 
Recently, it has been reported that the most important 
causes of 30-day mortality after TAVI are heart failure 
and cardiac arrest (40.3% of deaths) followed by vascular 
and bleeding complications (16.8% of deaths), stroke 
(10.9% of deaths), sepsis (10.9% of deaths) and cardiac 
tamponade (10.1% of deaths).11 Moreover, acute kidney 
injury stage ≥2, preprocedural hospitalisation for heart 
failure, periprocedural acute myocardial infarction and 
increased probrain natriuretic peptide have been iden-
tified as independent predictors of 30-day mortality.12 
Our analysis revealed no significant differences between 
Table 1 Baseline characteristics





Age (years) 82.29±5.67 82.67±6.35 0.377
Female gender, n(%) 207 (52.9) 208 (53.2) 1.000
Body mass index (kg/m2) 26.26±4.94 26.45±5.23 0.614
Risk assessment
  STS score 5.04±2.83 5.09±2.80 0.792
  Logistic EuroSCORE 18.02±11.15 18.08±13.23 0.945
Cardiac risk factors
  Diabetes mellitus, n (%) 82 (21.0) 108 (27.6) 0.037
  Hypertension, n (%) 323 (82.6) 327 (83.6) 0.775
  Dyslipidemia, n (%) 233 (59.6) 255 (65.2) 0.121
Clinical features
  Renal failure (GFR <60 mL/min/1.73 m2) 149 (38.3%) 96 (24.7%) <0.001
  COPD, n (%) 46 (11.8) 35 (9.0) 0.240
  Atrial fibrillation, n (%) 134 (34.3) 138 (35.3) 0.822
  Permanent pacemaker, n (%) 40 (10.2) 43 (11.0) 0.817
Past medical history
  Previous stroke or TIA, n (%) 34 (8.7) 44 (11.3) 0.283
  Carotid artery disease, n (%) 21 (5.5) 29 (10.6) 0.017
  Coronary artery disease, n (%) 231 (59.1) 249 (63.7) 0.212
  Previous myocardial infarction, n (%) 52 (13.3) 55 (14.1) 0.835
  Previous intervention, n (%) 108 (27.6%) 134 (34.3%) 0.053
  CABG 32 (8.5%) 41 (10.5%) 0.390
  PCI 86 (22.0%) 106 (27.2%) 0.097
  Peripheral vascular disease, n (%) 39 (10.0%) 24 (6.1%) 0.065
Echocardiographic findings
  Mean aortic valve area (cm2) 0.65±0.23 0.68±0.27 0.106
  Mean aortic valve gradient (mm Hg) 43.19±16.48 41.45±19.07 0.199
  LVEF (%) 55.50±14.21 54.18±15.50 0.239
  Moderate/severe mitral regurgitation 68 (18.9%) 58 (15.6%) 0.242
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventricular 
ejection fraction; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; 
TIA, transient ischaemic attack.
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Table 2 Procedural characteristics
Early generation TAVI 
devices
Newer generation TAVI 
devices P value
n=391 n=391
Procedure time (min) 68.76±34.16 63.24±27.81 0.014
Amount of contrast (mL) 234±99 161±57 <0.001
General anaesthesia, n (%) 66 (16.9%) 59 (15.1%) 0.558
Sheath size (mean±SD) 18.04±1.62 15.71±2.53 <0.001
Predilatation, n (%) 346 (88.5%) 230 (58.8%) <0.001
Postdilatation, n (%) 93 (23.6%) 76 (19.2%) 0.162
Concomitant percutaneous coronary intervention 23 (7.7%) 41 (11.5%) 0.113
Device features
  Medtronic CoreValve, n (%) 201 (51.4%)
  Edwards SAPIEN THV/XT, n (%) 190 (48.6%)
  Edwards SAPIEN 3, n (%) 190 (48.6%)
  BSC LOTUS, n (%) 96 (24.6%)
  Medtronic Evolut R, n (%) 105 (26.9%)
Postprocedure aortic regurgitation, n (%) n=387 n=389 <0.001
  None or mild 340 (87.9%) 377 (96.9%) <0.001
  Moderate or severe 47 (12.1%) 12 (3.1%) <0.001
Procedural complications
  Valve in series 7 (1.8%) 4 (1.0%) 0.546
  Repeat unplanned intervention 2 (0.5%) 6 (1.5%) 0.287
  Annulus rupture/aortic dissection, n (%) 0 (0.0%) 8 (2.0%) 0.008
  Valve dislocation/embolisation, n (%) 11 (4.0%) 3 (0.8%) 0.005
  Conversion to SAVR, n (%) 4 (1.0%) 2 (0.5%) 0.686
  Coronary artery occlusion, n (%) 3 (1.1%) 3 (0.8%) 0.696
BSC, Boston Scientific; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve.
Figure 2 Kaplan-Meier estimates of the VARC-2 early 
composite safety outcome. The blue line relates to the 
newer generation TAVI devices; the black line relates to the 
early generation TAVI devices. TAVI, transcatheter aortic valve 
implantation; VARC, Valve Academic Research Consortium.
Figure 3 Kaplan-Meier estimates of the VARC-2 early 
composite safety outcome landmark analysis between 0 
and 3 days and 4 and 30 days. The blue line relates to the 
newer generation TAVI devices; the black line relates to the 
early generation TAVI devices. TAVI, transcatheter aortic valve 
implantation; VARC, Valve Academic Research Consortium.
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groups related to these factors except for a lower rate of 
bleeding in patients treated with newer as compared with 
early generation devices, and accordingly there were no 
differences in terms of early all-cause or cardiovascular 
death. Of note, also non-cardiac causes, not related to 
the device features, importantly contribute to all-cause 
mortality.11 At the same time, there were no differences 
in the rates of cerebrovascular events between patients 
treated with early as compared with newer generation 
devices.
We documented a lower risk of valve migration or 
embolisation in patients treated with newer as compared 
with early generation devices. This finding can be 
explained by the full or partial repositionability of some 
of the newer generation THV devices and the advent of 
imaging tools to facilitate precise device positioning. In 
turn, we noted an increased risk of aortic annulus rupture 
or aortic dissection in patients treated with newer as 
compared with early generation devices despite a similar 
Table 3 Adjudicated clinical outcomes at 30 days follow-up




Newer generation vs early 
generation
Crude
n=391 n=391 HR (95% CI) P value
30-day follow-up
  Early safety composite end point, n (%) 83 (21.2) 81 (20.8) 0.98 (0.72 to 1.33) 0.876
  All-cause death, n (%) 19 (4.9) 15 (3.9) 0.80 (0.41 to 1.58) 0.519
  Cardiovascular death, n (%) 18 (4.6) 11 (2.8) 0.62 (0.29 to 1.31) 0.210
  CVE, n (%) 17 (4.4) 17 (4.4) 1.00 (0.51 to 1.97) 0.989
  Stroke 16 (4.1) 15 (3.9) 0.94 (0.47 to 1.91) 0.868
  Disabling stroke 14 (3.6) 9 (2.3) 0.64 (0.28 to 1.49) 0.301
  Non-disabling stroke 2 (0.5) 6 (1.6) 3.05 (0.61 to 15.09) 0.172
  Transient ischaemic attack 1 (0.3) 2 (0.5) 2.02 (0.18 to 22.25) 0.567
  Myocardial infarction, n (%) 2 (0.5) 2 (0.5) 1.00 (0.14 to 7.10) 1.000
  All-cause death or CVE, n (%) 26 (6.7) 29 (7.5) 1.13 (0.66 to 1.91) 0.661
  Cardiovascular death or CVE, n (%) 25 (6.4) 26 (6.7) 1.05 (0.61 to 1.81) 0.867
  Bleeding events, n (%) 125 (32.0) 96 (24.8) 0.74 (0.57 to 0.97) 0.028
  Life-threatening or disabling bleeding 33 (8.5) 18 (4.6) 0.54 (0.30 to 0.96) 0.036
  Major bleeding 71 (18.2) 42 (10.8) 0.58 (0.39 to 0.85) 0.005
  Minor bleeding 27 (7.0) 39 (10.1) 1.46 (0.90 to 2.39) 0.128
  Vascular access site and access-related 
complications, n (%)
97 (24.8) 93 (23.9) 0.96 (0.72 to 1.27) 0.757
  Major vascular complications 42 (10.7) 47 (12.1) 1.12 (0.74 to 1.70) 0.587
  Minor vascular complications 55 (14.1) 44 (11.3) 0.80 (0.54 to 1.18) 0.260
  Permanent pacemaker implantation 84 (21.7) 89 (23.2) 1.08 (0.80 to 1.45) 0.617
  Acute kidney injury, n(%) 27 (6.9) 17 (4.4) 0.63 (0.34 to 1.16) 0.138
  Stage 1, n (%) 18 (4.6) 2 (0.5) 0.11 (0.03 to 0.48) 0.003
  Stage 2, n (%) 0 (0.0) 5 (1.3) 11.00 (0.61 to 198.26) 0.062
  Stage 3, n (%) 9 (2.3) 10 (2.6) 1.12 (0.46 to 2.76) 0.800
 CVE, cerebrovascular event; TAVI, transcatheter aortic valve implantation.
Figure 4 Stratified analysis for the VARC-2 early composite 
safety outcome. eGFR, estimated glomerular filtration rate; 
LVEF, left ventricular ejection fraction; TAVI, transcatheter 
aortic valve implantation; VARC, Valve Academic Research 
Consortium.
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proportion of balloon-expandable valves in both groups. 
Oversizing of balloon-expandable THVs, higher degree 
of calcification of the left ventricular outflow tract and 
balloon postdilation have been associated with rupture 
of the aortic root.13 14 In addition, an oval rather than a 
round shape of the annulus may confer a higher risk of 
rupture. We did not systematically assess the degree of 
oversizing of the THV in relation to the annulus, and did 
not record the shape of the annulus, nor the extent or 
degree of calcification.
We found a significantly lower incidence of PVR in 
patients treated with newer as compared with early 
generation devices. Our results are consistent with the 
findings of a non-randomised study showing a lower risk 
of PVR among patients treated with Edwards SAPIEN 3 
(1.3%) compared with SAPIEN XT (5.3%) (P=0.04).15 
Low rates of PVR have also been reported in single-arm 
studies of patients treated with the Medtronic EVOLUT 
R16 and the Boston Scientific LOTUS system.17 Moderate 
and severe PVR have been associated with increased 
mortality at mid-term (>30 days),18 posing an important 
safety concern with regard to the extension of TAVI to a 
lower risk patient population. Newer generation devices 
allow for complete or partial valve repositionability and/
or feature external sealing cuffs or internal skirts to 
minimise the risk of PVR.6 In addition to unique device 
properties, the use of three-dimensional CT for accurate 
measurement of the aortic annulus and modest oversizing 
has been shown to result in a reduction of PVR.19 Lower 
rates of PVR with newer generation THVs may mitigate 
the risk of valve degeneration and reduce valve-related 
mortality during extended follow-up.20
We documented a decreased risk of bleeding among 
patients treated with newer as compared with early gener-
ation devices; the difference was driven by life-threat-
ening and major bleeding events. In turn, we found no 
difference in vascular access site complications between 
the two groups (table 3). Vascular access (transfemoral 
vs transapical), sheath diameter and closure devices 
have been identified as predictors of vascular access site 
complications.21–23 Previous studies reported vascular 
complications ranging from 6% to 20%.24 25 The wide 
range of vascular complications is likely influenced by 
differences in applied definitions of vascular complica-
tions across various studies. Some of the newer gener-
ation devices feature a lower delivery system profile 
and have been shown to decrease the risk of access 
site complications.26 However, other newer generation 
devices, such as the LOTUS valve system, continue to use 
delivery sheath profiles comparable to early generation 
devices. In addition, a lower delivery sheath diameter in 
most newer generation devices was accompanied by an 
extension of transfemoral access to patients with more 
advanced peripheral vascular disease, which may have 
counterbalanced the intuitive benefit of lower profile 
delivery sheaths to a certain degree.
We found a similar rate of permanent pacemaker 
implantations (PPI) in patients treated with early versus 
newer generation devices. A significant difference in 
rates of AV conduction disturbances has been described 
between early generation balloon-expandable versus 
self-expandable devices, resulting in PPI in 5%–12% 
of patients after Edwards SAPIEN implantation versus 
24%–33% after Medtronic CoreValve implantation.27 
Recently, a trial revealed a significant increase in rates of 
PPI following SAPIEN 3 implantation as compared with 
the early generation XT (19.1% vs 12.2%, P=0.046).28 
Conversely, the reported rate of PPI at 30 days following 
newer generation Medtronic Evolut R implantation was 
11.7%,16 which is less than the 30-day PPI rates reported 
after early generation Medtronic CoreValve implantation 
(33.3%).27 Finally, rates of AV conduction disturbances 
were found to be relatively high after LOTUS valve 
implantation in both the REPRISE II study29 and the UK 
registry17 with PPI in 31.9% and 31.8% of patients, respec-
tively. The impact of PPI on clinical outcomes and quality 
of life is a matter of ongoing debate, due to conflicting 
reported data in relation to 1-year mortality.29–31 Ventric-
ular dyssynchrony caused by chronic right ventricular 
stimulation is one of the postulated mechanisms that 
adversely affect long-term prognosis among patients with 
a high degree of pacemaker dependency.
lIMItAtIons
First, the analysis is open to biases inherent to longitu-
dinal comparisons. Patients were not randomised to the 
respective treatment group and despite propensity score 
matching, hidden confounders may have biased our 
results. Clinical outcomes result from a combination of 
patient characteristics, device features and procedural 
details such as the learning curve. While we corrected for 
the former two, the latter factor was not corrected for and 
may have biased the presented results to a certain degree. 
Second, the number of patients included in our analysis 
is limited and the follow-up does not extend beyond 30 
days. Third, we did not capture data on extent and distri-
bution of calcification in our database, which may have 
confounded the annular rupture rates. Fourth, we eval-
uated only newer generation THV devices used in our 
clinical practice, which represent only a portion of the 
CE-marked second-generation prosthesis. Therefore, 
our findings cannot be extended to all newer generation 
THV devices. And finally, early and newer generation 
devices within the two groups differ in particular char-
acteristics of the device and the delivery system, and not 
all devices share the same newer generation features. In 
order to mitigate confounding by delivery mechanism, 
we therefore matched separately for ‘self-expandable’ 
and ‘non-self-expandable’ devices.
ConClusIons
In a propensity score matched analysis, we observed 
comparable VARC-2 early safety composite outcomes 
in patients treated with early as compared with newer 
generation THV devices. Newer generation THV devices 
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showed a significant reduction in terms of moderate-to-se-
vere PVR at 30 days, and a lower rate of THV migration 
and bleeding complications. Further studies are required 
to evaluate the long-term effectiveness of newer THV 
devices. A tailored use of THV devices based on patient 
anatomical and prosthesis characteristics may exploit the 
full potential of these new devices.
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